Abstract
Background Treatments aimed at hastening recovery from disorders of consciousness (DOC; e.g., coma, the vegetative state) have lagged behind a rapidly advancing science of these conditions. In part, this is due to the difficulty in selectively targeting the many deep regions of the brain known to be key for recovery from DOC. The (re)emergence of low intensity focused ultrasound (LIFU) neuromodulation addresses this gap by providing a non-invasive, safe, and relatively low-cost means to exert neuromodulatory effects, anywhere in the brain, with relatively high spatial precision.
Methods As part of this first-in-man clinical trial, a cohort of 10 patients with chronic DOC underwent two sessions of MR-guided thalamic LIFU, with concomitant functional neuroimaging, one week apart. Behavioral responsiveness, measured with the Coma Recovery Scale Revised (CRS-R), was assessed at multiple time-points both before and after each LIFU session. Changes in clinical score before and after each session were compared within subjects.
Results This convenience sample of sample of chronic DOC patients included, at entry, 4 Minimally Conscious State plus (MCS+), 4 Minimally Conscious State minus (MCS-) and 2 Vegetative State (VS) patients (6 male; mean age = 39.1, mean time since injury = 56.75 months; 4 anoxic and 6 traumatic injuries). We find a significant linear increase over time in CRS-R total score with thalamic LIFU exposure. Functional imaging reveals changes in brain-wide activity and thalamo-cortical connectivity of the targeted thalamus (but not the contralateral, non-targeted, thalamus), during LIFU administration. Strikingly, these effects are associated with the degree of behavioral recovery observed following exposure.
Discussion Collectively, these results are the first to suggest the efficacy of thalamic LIFU for the treatment of chronic DOC and extend our previous investigations in acute DOC populations. Indeed, results from both cohorts support the safety, feasibility, and preliminary efficacy of LIFU, as evaluated by gold-standard clinical assessments. Moreover, imaging results in both datasets provide a convergent biological link uniting neuromodulatory thalamic LIFU and the observed behavioral recovery. These first-in-man findings provide a key foundation to motivate further exploration of this technique (e.g., LIFU parameterization, optimal number and timing of exposures) and invite a sham-control clinical trial, in a larger cohort, to assess, in a blinded fashion, the technique’s efficacy.
Clinical Trial number, date of submission, date of first enrollment, registration link:
NCT02522429
August 13, 2015
March 10, 2016
Competing Interest Statement
NMS is a consultant to the BrainSonix Corp, which manufactures the device used in this study.
Clinical Trial
NCT02522429
Funding Statement
This study was funded by the Tiny Blue Dot Foundation and the Dana Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by UCLA's IRB under the title: "Thalamic Low Intensity Focused Ultrasound in severe Brain Injury" (IRB#14-001749).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵‡ Joint last authors
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos